98%
921
2 minutes
20
A 59-year-old man with metastatic melanoma and brain metastases underwent brain radiotherapy. Following treatment, he developed neurological symptoms, prompting further evaluation. To assess the treatment response and possibility of Lutetium-177-FAPI therapy, both 18F-FDG PET/CT and 68Ga-FAPI-46 PET/CT scans were performed. The 18F-FDG PET/CT was inconclusive due to posttreatment changes, making it challenging to distinguish between tumor progression and therapy-related alterations. In contrast, the 68Ga-FAPI-46 PET/CT revealed multiple areas of increased FAPI uptake, indicative of viable residual lesions and consistent with MRI findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/RLU.0000000000005985 | DOI Listing |
Int J Surg
September 2025
Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, Key Laboratory of Pulmonary Diseases of National Health Commission, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Background: Precise preoperative discrimination of invasive lung adenocarcinoma (IA) from preinvasive lesions (adenocarcinoma in situ [AIS]/minimally invasive adenocarcinoma [MIA]) and prediction of high-risk histopathological features are critical for optimizing resection strategies in early-stage lung adenocarcinoma (LUAD).
Methods: In this multicenter study, 813 LUAD patients (tumors ≤3 cm) formed the training cohort. A total of 1,709 radiomic features were extracted from the PET/CT images.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Haematology and Haemato-Oncology, Aster Medcity, Kochi, Kerala, India.
Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans cell histiocytosis with multiple organ involvement. Being a rare disease with variable clinical manifestations, it is often difficult to diagnose. F-2-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a vital role in assessing disease extent and severity, diagnosis, treatment response and is a potential biomarker for BRAF mutation.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Lung cancer is the leading cause of cancer and cancer-related deaths, and India ranks the fourth highest country. Lung cancer is a highly aggressive malignancy with a tendency for rapid progression, making early detection and prompt treatment essential for improving patient outcomes. Lung cancer can spread locally into surrounding tissue as well as travel through lymphatics to other parts of the body, most often to bone, brain, liver, and adrenal glands.
View Article and Find Full Text PDFMini Rev Med Chem
September 2025
Department of PET/CT Diagnostic Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China.
The diagnosis of adrenocortical tumors remains clinically challenging due to overlapping morphological and functional features between benign, malignant, and hormonally active lesions. Malignant and functional tumors are frequently associated with poor prognosis. Traditional morphological imaging methods, such as CT and MRI, cannot reliably distinguish lesion types.
View Article and Find Full Text PDF